Lisa Lancaster
Vanderbilt University
69 Papers
155 Citations
Lisa Lancaster is an academic researcher from Vanderbilt University. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Medicine. The author has an hindex of 25, co-authored 43 publications.
Chat about Author
Papers
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
Talmadge E. King,Williamson Z. Bradford,Socorro Castro-Bernardini,Elizabeth A. Fagan,Ian Glaspole,Marilyn K. Glassberg,Eduard Gorina,Peter Hopkins,David Kardatzke,Lisa Lancaster,David J. Lederer,Steven D. Nathan,Carlos Alberto de Castro Pereira,Steven A. Sahn,Robert Sussman,Jeffrey J. Swigris,Paul W. Noble +16 more
TL;DR: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis.
Short telomeres are a risk factor for idiopathic pulmonary fibrosis
Jonathan K. Alder,Julian J.-L. Chen,Lisa Lancaster,Sonye K. Danoff,Shu Chih Su,Joy D. Cogan,Irma Vulto,Mingyi Xie,Xiaodong Qi,Rubin M. Tuder,John A. Phillips,Peter M. Lansdorp,James E. Loyd,Mary Armanios +13 more
TL;DR: Short telomeres are a signature in IIPs and likely play a role in their age-related onset, and the clustering of cryptogenic liver cirrhosis with IPF suggests that the telomere shortening can contribute to what appears clinically as idiopathic progressive organ failure in the lung and the liver.
803
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis.
Tasha E. Fingerlin,Elissa Murphy,Weiming Zhang,Anna L. Peljto,Kevin K. Brown,Mark P. Steele,James E. Loyd,Gregory P. Cosgrove,David A. Lynch,Steve D. Groshong,Harold R. Collard,Paul J. Wolters,Williamson Z. Bradford,Karl Kossen,Scott D. Seiwert,Roland M. du Bois,Christine Kim Garcia,Megan S. Devine,Gunnar Gudmundsson,Helgi J Isaksson,Naftali Kaminski,Yingze Zhang,Kevin F. Gibson,Lisa Lancaster,Joy D. Cogan,Wendi R. Mason,Toby M. Maher,Philip L. Molyneaux,Athol U. Wells,Miriam F. Moffatt,Moisés Selman,Annie Pardo,Dong Soon Kim,James D. Crapo,Barry J. Make,Elizabeth A. Regan,Dinesha Walek,Jerry Daniel,Yoichiro Kamatani,Diana Zelenika,Keith P Smith,David McKean,Brent S. Pedersen,Janet Talbert,Ravin N. Kidd,Cheryl Markin,Kenneth B. Beckman,Mark Lathrop,Mark Lathrop,Marvin I. Schwarz,David A. Schwartz +50 more
TL;DR: The results suggest that genes involved in host defense, cell-cell adhesion and DNA repair contribute to risk of fibrotic IIPs.
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.
Roland M. du Bois,Derek Weycker,Carlo Albera,Williamson Z. Bradford,Ulrich Costabel,Alex Kartashov,Lisa Lancaster,Paul W. Noble,Steven A. Sahn,Javier Szwarcberg,Michiel Thomeer,Dominique Valeyre,Talmadge E. King +12 more
TL;DR: The 6-minute-walk test is a reliable, valid, and responsive measure of disease status and a valid endpoint for clinical trials in IPF.
Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy.
TL;DR: Therapeutic interventions aimed at limiting NF-kappaB activation and down-regulating production of inflammatory mediators could prove to be beneficial in decreasing host-derived tissue injury and organ dysfunction.